Jason Gallagher, PharmD, discusses the clinical implications of eravacycline for the treatment of intra-abdominal infections.
Jason Gallagher, PharmD, clinical professor, Temple University School of Pharmacy, discusses the clinical implications of eravacycline for the treatment of intra-abdominal infections.
Interview Transcript (modified slightly for readability):
“Eravacycline is one of several new tetracyclines being developed. It’s a fluorocycline-type tetracycline. This drug is active against resistant Enterobacteriaceae and some gram-positive organisms as well. It’s fairly broad in its spectrum; it does not have activity against Pseudomonas similar to tigecycline or the other tetracyclines.
It’s been studied several times for complicated intra-abdominal infections and complicated urinary tract infections. The urinary tract infection studies were failures so we’re clearly not going to see it used for that.
But, the intra-abdominal infection studies look very good and I think there’s a good chance that it will be approved for that, where it will be an alternative regimen to some of the other therapies we have for intra-abdominal infections, in patients at risk or who have highly resistant organisms such as carbapenem-resistant Enterobacteriaceae (CRE), which the drug is potent against.”